JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorJenKem Technology Co., Ltd.
About this trial
This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.
Eligibility criteria
Qualifiers
Sign and date the informed consent form prior to the start of any study-specific qualification procedures.
Female aged ≥18 years.
Has ECOG PS of ≤1.
Life expectancy ≥ 3months.
Disqualifiers
None
Trial design
Treatments tested in this trial
- JK-1201I
Treatment groups
25 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov